People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Pharmaceuticals, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Verastem, Inc. | — | Pharmaceuticals | Series C | $163.2M | $3.5B | 2020 |
| TScan Therapeutics, Inc. | — | Biotechnology | Series C | $123.3M | $3.3B | 2019 |
| Gi Dynamics, Inc. | — | Biotechnology | Series B | $90.1M | $85.7M | 2018 |
| HeartWare International, Inc. | — | Other Health Care | Series C | $55.2M | $5.0M | 2009 |
| Euthymics Bioscience, Inc. | — | Biotechnology | Series B | $31.3M | $11.9M | 2017 |
| Gila Therapeutics, Inc. | — | Biotechnology | Seed | $6.2M | $2.7M | 2022 |
Timothy Barberich at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Timothy Barberich on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Campbell Murray | 2 | 9 |
| Christoph Westphal | 2 | 8 |
| Timothy J. Barberich | 2 | 7 |
| Scott Schorer | 2 | 2 |
| Seth Harrison | 1 | 19 |
| Robert Thomas | 1 | 8 |
| Robert Crane | 1 | 7 |
| DANIEL MOORE | 1 | 6 |
| Steve Kraus | 1 | 6 |
| Ittai Harel | 1 | 6 |
| Michael A. Carusi | 1 | 6 |
| Douglas A. Branch | 1 | 5 |
| Praveen Tyle | 1 | 5 |
| Jon Freeman | 1 | 5 |
| Andrew Hedin | 1 | 5 |
| Paul Weiss | 1 | 5 |
| John K. Clarke | 1 | 5 |
| Brigitte Smith | 1 | 5 |
| David McIntyre | 1 | 5 |
| Douglas Godshall | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.